

# Current Issues in Pharmacy and Medical Sciences

Formerly ANNALES UNIVERSITATIS MARIAE CURIE-SKŁODOWSKA, SECTIO DDD, PHARMACIA

journal homepage: <https://czasopisma.umlub.pl/curipms>



## Impact of vitamin D deficiency on reproductive dysfunction in West Algeria women of reproductive age

ANFAL BELKACEM<sup>1,2</sup> , SIHEME OUALI<sup>1,2</sup> , NORIA HARIR<sup>1,2\*</sup> , FERIEL SELLAM<sup>3</sup> ,  
KHALIDA ZEMRI<sup>1,2</sup> , CHAHANZ HADJ SLIMANE MIRALI<sup>4</sup> ,  
MALIKA BENDAHEMAN<sup>1,2</sup> , FERYEL SENOUSSAOUT<sup>5</sup> , SEIF EDDINE BENARIBA<sup>6</sup>

<sup>1</sup> Department of Biology, Faculty of Natural Sciences and Life, Djillali Liabés University, Sidi-Bel-Abbés, Algeria

<sup>2</sup> Laboratory of Molecular Microbiology Health and Proteomics, Faculty of Natural Sciences and Life, Djillali Liabés University, Sidi-Bel-Abbés, Algeria

<sup>3</sup> National Research Center of Biotechnology, CRBT, Algeria

<sup>4</sup> Centre El Assrar, Hai Emir Abdelkader Bir El Djir, Oran, Algeria

<sup>5</sup> Medically Assisted Procreation Clinic el Anis, Djir, Oran, Algeria

<sup>6</sup> Medically Assisted Procreation Clinic, Tiaret, Algeria

### ARTICLE INFO

Received 13 January 2024

Accepted 16 June 2024

### Keywords:

hormones,  
vitamin D supplementation,  
Hypovitaminosis D,  
female fertility,  
infertility duration.

### ABSTRACT

In addition to sex steroid hormones, vitamin D has a modulatory reproductive action due to the vitamin D receptor and vitamin D metabolizing enzymes that are found in human reproductive tissues. This study aimed to evaluate and explore the impact of vitamin D on female infertility. Authors conducted a prospective study of 394 infertile women from the region of Tiaret (western Algeria).

Authors study revealed a predominance of hypovitaminosis in 80.8% of all patients, with no significant relationship between vitamin D status and age. However, a significant association between residence, Body Mass Index and vitamin D was found ( $P < 0.0001$ ). The association of 25(OH)D and certain pathologies (Polycystic ovary syndrome, endometriosis, miscarriage and irregular menstrual cycle) was very significant ( $P < 0.0001$ ). Women with vitamin D deficiency were the most affected by uterine and ovarian abnormalities. An inverse correlation was highlighted between vitamin D and different hormones, infertility duration and supplementation. Moreover, women with long lasting infertility (55-96 months and over 96 months) were deficient in vitamin D (31.3% and 19.5%, respectively). In addition, miscarriages were more noted in vitamin D deficient women (96 cases, 36.6%); however, the majority of women with normal vitamin D status had no history of miscarriages (93.3%)  $P \chi^2 < 0.0001$ .

Hypovitaminosis D is associated with long durations of infertility, high number of miscarriages, a significant prevalence of Polycystic ovary syndrome, irregular menstrual cycles. Thus, good control of vitamin D status is a necessity for improving female fertility.

### INTRODUCTION

In literature, vitamin D is defined as a steroid hormone produced by the skin after sun exposure with a rate of 80% to 90%. A minor quantity of total body vitamin D, however, comes from food and dietary supplements [1]. Vitamin D deficiency is prevalent in females of childbearing age [2]. The main causes of this deficiency are obesity, lifestyle changes and reduced sun exposure [3]. Research demonstrates that, in addition to sex steroid hormones, vitamin D regulates reproductive actions. This is due to the presence

of vitamin D receptor (VDR) and vitamin D metabolizing enzymes in human reproductive tissues [4]; including the ovary, uterus, placenta and pituitary, which links vitamin D to reproductive health [5].

The World Health Organization (WHO) has approximated that 48 million couples are affected by infertility, with a global estimated prevalence of 10-15% [6]; polycystic ovarian syndrome (PCOS) [7], obesity [8], endometriosis [9], are the main causes of female infertility.

Several studies have revealed correlations between these pathologies and vitamin D deficiency. However, those that considered all parameters related to female infertility with

\* Corresponding author

e-mail: [noria.harir@univ-sba.dz](mailto:noria.harir@univ-sba.dz)

low vitamin D levels in west Algeria were very rare, so we conducted a prospective study on Algerian women of childbearing age to elucidate the role of vitamin D on female fertility and its impact on the most frequent conditions associated with impaired female fertility such as polycystic ovary syndrome (PCOS), endometriosis and regularization of the menstrual cycle.

## MATERIALS AND METHODS

### Study setting and period

Our survey was carried out at the level of the medically assisted procreation clinic in the region of Tiaret (Western Algeria, North Africa) along a period of one year from September 2021 to September 2022.

### Study design

A prospective epidemiological study was performed in order to assess the relationship between vitamin D deficiency and impaired female fertility.

### Sample size and sampling procedure

Our study was carried out on a sample of 394 infertile women. All patients with fertility disorders aged between 18 and 40 who agreed to participate in our study and gave their consent were included. Patients aged over 40 and those supplemented with vitamin D were excluded as were women under specific drugs effects inducing vitamin D deficiency such as corticosteroids and antiepileptic drugs.

### Data collection tools and procedures

Studied parameters were: age, residence, weight status, 25 OH vitamin D levels, presence of certain pathologies (PCOS, endometriosis, uterine abnormalities, ovarian abnormalities, miscarriages), menstrual cycle regularity, hormonal profile (FSH, LH, estrogen, progesterone) and the consequences of vitamin D supplementation.

All participants were classified into 3 subgroups: Deficiency (serum 25OH-D <20 ng/ml), Insufficient (serum 25OH-D ≥20 to <30 ng/ml), and Normal (serum 25OH-D ≥30 ng/ml) [10].

### Data analysis

The data collected during the survey were assessed using statistical software (SPSS Inc., Chicago, IL, USA) version 25, and the results were considered significant when  $p < 0.05$ . To compare qualitative values, we used the chi-square test, while the quantitative values were expressed as mean  $\pm$  standard deviation. Pearson's correlation and the one-way ANOVA test were applied for the comparative study.


### Ethics

Considering Decree No. 387 (article 25) dated 31 July 2006 about ethical trials in Algeria, we obtained the required access authorizations to the concerned health facilities to accomplish our study protocol. The medical committee of the Tiaret region medically assisted procreation clinic and the biology department of Djillali Liabes University approved the study. Written consent was obtained.

## RESULTS

Into our study, 394 infertile women were recruited. They had a mean age of  $33.23 \pm 6.16$  years. A low rate of 25-hydroxyvitamin D (deficiency) was mainly noted in 262 cases, (66.7%) and 56 cases had an insufficient level (14.2%); while only 75 cases (19.1%) had normal vitamin D levels. No significant relationship was found between Vitamin D status and age. A significant link between residence, BMI and vitamin D was, however, found in our series ( $P\chi^2 < 0.0001$ ). Most obese, overweight, and lean women had Vitamin D deficiency at 27.5%, 19.8% and 12.2%, respectively, while normal vitamin D levels were more noticeable in women with normal weight status at 84 %. Moreover, hypovitaminosis was more dominant in women from urban areas (210 cases), compared to 108 cases of rural women.

Pearson correlation revealed that the more that serum level indicates increase of 25-hydroxyvitamin D, the greater the decrease in duration of infertility ( $P < 0.0001$ ) (Figure 1A). Women with long durations of infertility (55-96 months and over 96 months) were deficient in vitamin D (31.3% and 19.5%, respectively) compared to the group with normal serum vitamin D levels (8% and 0%, respectively) (Table 1).



**Figure 1.** Linear correlation between vitamin D level and infertility duration, hormone profile, and duration of supplementation

Our study highlighted a significant prevalence of PCOS (26.21%), most were deficient in serum vitamin D level (87 cases), and the link between vitamin D deficiency and PCOS was significant  $P\chi^2 < 0.000$ . Besides PCOS, polycystic ovary was also more noted in vitamin D deficient patients (14 cases). Concerning endometriosis, our results did not demonstrate a relationship with vitamin D deficiency.

With regard to miscarriages, we found that the highest number of pregnancy losses occurred in the vitamin D deficient women group (36.6% for 1-3 miscarriages and 2.3% for 3-5 miscarriages), while most females with normal vitamin D status had no history of miscarriages (93.3%)  $P\chi^2 < 0.0001$ . Furthermore, the majority of Vitamin D

deficient patients group had irregular menstrual cycles (58.4%); whereas 84% of all women with normal vitamin D status had no cycle disorders.

**Table 1.** Relationship of vitamin D with age, Body Mass Index, area, and infertility duration

|                               |           | Vitamin D status |               |               | P Value |
|-------------------------------|-----------|------------------|---------------|---------------|---------|
|                               |           | Deficiency       | Insufficient  | Normal        |         |
| Age (years)                   | Mean±SD   | 33.15±5.74       | 34.18±7.62    | 32.83±6.38    | 0.429   |
|                               | 21-30     | 108<br>(41.2%)   | 16<br>(28.6%) | 34<br>(45.3%) | 0.249   |
|                               | 31-40     | 108<br>(41.2%)   | 25<br>(44.6%) | 26<br>(34.7%) |         |
|                               | >40       | 46<br>(17.6%)    | 15<br>(28.6%) | 15(20%)       |         |
| BMI (kg/m <sup>2</sup> )      | Mean±SD   | 25.21±5.85       | 25.54±6.35    | 23.88±3.17    | 0.13    |
|                               | <18,5     | 32<br>(12.2%)    | 10<br>(17.9%) | 0<br>(0.0%)   | <0.0001 |
|                               | 18,5-24,9 | 106<br>(40.5%)   | 16<br>(28.6%) | 63<br>(84%)   |         |
|                               | 25-29,9   | 52<br>(19.8%)    | 15<br>(26.8%) | 11<br>(14.7%) |         |
|                               | >= 30     | 72<br>(27.5%)    | 15<br>(26.8%) | 1<br>(1.3%)   |         |
|                               |           |                  |               |               |         |
| Area                          | Urban     | 170<br>(64.9%)   | 40<br>(71.4%) | 30<br>(40%)   | <0.0001 |
|                               | Rural     | 92<br>(35.1%)    | 16<br>(28.6%) | 45<br>(60%)   |         |
| Infertility duration (Months) | Mean±SD   | 5.81±4.39        | 4.57±3.68     | 2.29±1.44     | <0.0001 |
|                               | <=12      | 30<br>(11.5%)    | 15<br>(26.8%) | 35<br>(46.7%) | <0.0001 |
|                               | 13-54     | 99<br>(37.8%)    | 15<br>(26.8%) | 34<br>(45.3%) |         |
|                               | 55-96     | 82<br>(31.3%)    | 15<br>(26.8%) | 6<br>(8%)     |         |
|                               | >96       | 51<br>(19.5%)    | 11<br>(19.6%) | 0<br>(0.0%)   |         |
|                               |           |                  |               |               |         |

The most affected category by uterine abnormalities was that of women who had vitamin D deficiency (40 cases of uterine fibroids, 10 cases of uterine malformation, and 5 cases of tubal obstruction). Statistical analysis revealed that the relationship between vitamin D and these pathologies was significant – as illustrated in Table 2.

**Table 2.** Relationship of vitamin D status with female pathologies

| Pathologies           |                   | Vitamin D status |               |               | P Value |
|-----------------------|-------------------|------------------|---------------|---------------|---------|
|                       |                   | Deficiency       | Insufficient  | Normal        |         |
| PCOS                  | No                | 175<br>(66.8%)   | 46<br>(82.1%) | 69<br>(92%)   | <0.0001 |
|                       | Yes               | 87<br>(33.2%)    | 10<br>(17.9%) | 6<br>(8%)     |         |
| Endometriosis         | No                | 260<br>(99.2%)   | 53<br>(94.6%) | 63<br>(84%)   | <0.0001 |
|                       | Yes               | 2<br>(0.8%)      | 3<br>(5.4%)   | 12<br>(16%)   |         |
| Miscarriage           | 1-3 miscarriages  | 96<br>(36.6%)    | 0<br>(0.0%)   | 5<br>(6.7%)   | <0.0001 |
|                       | 3-5 miscarriages  | 6<br>(2.3%)      | 0<br>(0.0%)   | 0<br>(0.0%)   |         |
|                       | without a history | 160<br>(61.1%)   | 56<br>(100%)  | 70<br>(93.3%) |         |
|                       |                   |                  |               |               |         |
| Menstrual cycles      | irregular         | 153<br>(58.4%)   | 15<br>(26.8%) | 12<br>(16%)   | <0.0001 |
|                       | regular           | 109<br>(41.6%)   | 41<br>(73.2%) | 63<br>(84%)   |         |
| Ovarian abnormalities | ovarian fibroids  | 5<br>(1.9%)      | 3<br>(5.4%)   | 5<br>(6.7%)   | <0.001  |
|                       | polycystic ovary  | 14<br>(5.3%)     | 4<br>(7.1%)   | 8<br>(10.7%)  |         |
|                       | PCOS              | 87<br>(33.2%)    | 10<br>(17.9%) | 6<br>(8%)     |         |
|                       | a single ovary    | 1<br>(0.4%)      | 1<br>(1.8%)   | 1<br>(1.3%)   |         |
|                       | without anomalies | 155<br>(59.2%)   | 38<br>(67.9%) | 55<br>(73.3%) |         |
|                       |                   |                  |               |               |         |
| Anomalies Uterine     | uterine fibroid   | 40<br>(15.3%)    | 5<br>(8.9%)   | 21<br>(28%)   | <0.0001 |
|                       | uterine deformity | 10<br>(3.8)      | 0<br>(0%)     | 0<br>(0%)     |         |
|                       | tubal obstruction | 5<br>(1.9%)      | 5<br>(8.9%)   | 0<br>(0%)     |         |
|                       | without anomalies | 207<br>(79%)     | 46<br>(82.1%) | 54<br>(72%)   |         |
|                       |                   |                  |               |               |         |
|                       |                   |                  |               |               |         |

The association between the studied hormones and the vitamin D status is described in Table 3. A significant relationship between these two parameters was noted with the level of FSH, progesterone and estrogen ( $P\chi^2<0.05$  for FSH,  $P\chi^2<0.0001$  for progesterone and estrogen). In contrast, the LH level results were insignificant ( $P\chi^2>0.05$ ).

**Table 3.** Relationship of vitamin D status with hormonal profile

|                     |         | Vitamin D status |                  |                  | P Value |
|---------------------|---------|------------------|------------------|------------------|---------|
|                     |         | Deficiency       | Insufficient     | Normal           |         |
| FSH (mUI /ml)       | Mean±SD | 4.7±2.74         | 5.03±1.79        | 7.06±2.16        | <0.0001 |
|                     | Low     | 46<br>(17.6%)    | 5<br>(8.9%)      | 5<br>(6.7%)      | 0.038   |
|                     | High    | 5<br>(1.9%)      | 0<br>(0.0%)      | 0<br>(0.0%)      |         |
|                     | normal  | 211<br>(80.5%)   | 51<br>(91.1%)    | 70<br>(9.3%)     |         |
| LH (mUI/ml)         | Mean±SD | 2.37±1.81        | 2.19±1.29        | 2.84±1.65        | 0.062   |
|                     | Low     | 40<br>(15.3%)    | 5<br>(8.9%)      | 5<br>(6.7%)      | 0.109   |
|                     | High    | 5<br>(1.9%)      | 0<br>(0.0%)      | 0<br>(0.0%)      |         |
|                     | normal  | 217<br>(82.8%)   | 51<br>(91.1%)    | 70<br>(9.3%)     |         |
| Progesterone (µg/l) | Mean±SD | 0.25±0.22        | 0.37±0.44        | 1.18±0.32        | <0.0001 |
|                     | Normal  | 165<br>(63%)     | 36<br>(64.3%)    | 75<br>(100%)     | <0.0001 |
|                     | Low     | 97<br>(37%)      | 20<br>(35.7%)    | 0<br>(0.0%)      |         |
| Estrogen (pg/ml)    | Mean±SD | 89.81<br>±66.55  | 146.61<br>±81.13 | 146.02<br>±42.04 | <0.0001 |
|                     | Normal  | 165<br>(63%)     | 36<br>(64.3%)    | 75<br>(100%)     | <0.0001 |
|                     | Low     | 97<br>(37%)      | 20<br>(35.7%)    | 0<br>(0.0%)      |         |

Hormonal assessment showed that abnormal levels were mostly found in the deficient vitamin D group than in those with normal levels of this vitamin (Table 3). In addition, we found a positive correlation between vitamin D levels and FSH, progesterone and estrogen hormones ( $P<0.0001$ ) (Figure 1A, B, C). This was similarly so with kLH, but without significance ( $P>0.05$ ) (Figure 1D).

Our study revealed that an important number of patients suffering from hypovitaminosis D were supplemented with vitamin D (171 cases), while 222 women had not complied with this vitamin supplementation. Vitamin D3 dosage in most of patients was of 200,000 IU with an interval of 15 days, only 11 cases (4.2%) complied with a regulated treatment regimen for 6 months and two therein had a pregnancy (Table 4). The correlation between vitamin D and the duration of supplementation revealed that more that

**Table 4.** Relationship of vitamin D status with data on Vitamin D supplementation

|                                      |                 | Vitamin D status |               |               | P Value |
|--------------------------------------|-----------------|------------------|---------------|---------------|---------|
|                                      |                 | Deficiency       | Insufficient  | Normal        |         |
| Vitamin D supplementation            | Yes             | 144<br>(55%)     | 26<br>(46.4%) | 1<br>(1.3%)   | <0.0001 |
|                                      | No              | 118<br>(45%)     | 30<br>(53.6%) | 74<br>(98.7%) |         |
| Duration of supplementation (months) | Mean±SD         | 0.76<br>±1.203   | 0.5<br>±0.57  | 0.01<br>±0.11 | <0.0001 |
|                                      | Unsupplemented  | 118<br>(45%)     | 30<br>(53.6%) | 74<br>(98.7%) | <0.0001 |
|                                      | ≥ 1 month       | 133<br>(50.8%)   | 26<br>(46.4%) | 1<br>(1.3%)   |         |
|                                      | 2-3 months      | 0<br>(0%)        | 0<br>(0%)     | 0<br>(0%)     |         |
|                                      | 4-6 months      | 11<br>(4.2%)     | 0<br>(0%)     | 0<br>(0%)     |         |
| Post-supplementation observation     | Pregnancy       | 2<br>(0.8%)      | 0<br>(0%)     | 0<br>(0%)     | <0.001  |
|                                      | Without results | 142<br>(99.2%)   | 56<br>(100%)  | 75<br>(100%)  |         |

the level of vitamin D increased, the greater the decrease in supplementation duration ( $P < 0.0001$ ) (Figure 1F).

## DISCUSSION

Our study revealed a predominance of hypovitaminosis in our infertile patients, which indicates a clear link between normal vitamin D status and improved fertility. Indeed, the role of vitamin D3 in the female reproductive tract has been extensively investigated because its receptor is abundant in reproductive organs, including the ovary. Of note, the expression of vitamin D3 receptor in the ovary is as an extra-renal site. Furthermore, the influence of vitamin D3 on follicular development and ovarian steroidogenesis has been investigated [11].

Bhattarai *et al.*, [1] stated that vitamin D synthesis is also influenced by age (decreased production capacity). The elderly, particularly those living in institutions, represent a population with a higher risk of vitamin D deficiency (low exposure, increased needs and production of urine, as well as a decrease in dietary vitamin D, renal production, VDR level).

In Algeria, the prevalence of female obesity in 2013 was estimated at 30.1% [12]. Data from meta-analyses consistently support an inverse association of vitamin D levels with body weight [13] and that low vitamin D intake could be an obesity major predictor. This stated outcome is similar to our results. Up today, it is not clear if vitamin D insufficiency is a consequence of obesity or the situation is reversed. Recent findings have stated that volumetric dilution of vitamin D is the most frequent mechanism of the inverse relationship between serum vitamin D levels and BMI. Although obese and lean subjects have similar amounts of VD, in overweight individuals, VD is distributed in a larger volume, making serum concentrations lower. Of note, 25(OH)D is distributed mostly in serum, muscles, fat and liver – and organs that are more important in cases of obesity [14].

Our study revealed a significant association between residence and vitamin D status, with rural women being less deficient in vitamin D than women from urban areas. Indeed, direct sunlight exposure is more noted in rural regions than in urban areas. Vitamin D is the sunshine vitamin. When exposed to the sun, the 7-dehydrocholesterol found in the skin absorbs ultraviolet B (UVB) rays and converts them into pre-vitamin D3. As pre-vitamin D3 is thermodynamically unstable, it isomerizes within a few hours to form vitamin D3. The body has a great capacity to produce vitamin D3, and reasonable exposure to sunlight can enhance 25-hydroxyvitamin D blood levels [15].

Fung *et al.*, [16] indicated that poor levels of 25(OH)D are associated with a 76% reduction in the chances of pregnancy. These data explain the significant inverse correlation between the vitamin D level and infertility duration noted in our study.

There are several studies [17,18] correlating low 25(OH)D status with PCOS characteristics, which is consistent with our results. Interestingly, in 2019, epidemiological studies in Algeria noted 499,279 cases of PCOS [19]. Vitamin D has been suggested to play an important role in PCOS with regard to several aspects, including menstrual regularity,

fertility, BMI, lipid profile, insulin resistance and cardiovascular risk [18].

Furthermore, the effects of vitamin D can also be explained by its immunomodulatory power. Indeed, different alterations can be observed in cases of vitamin D deficiency such as dominance of Th2 cytokines [20] and reduction in the production of inflammatory cytokines [21]. Additionally, vitamin D has been shown to inhibit the production of tumor necrosis factor-alpha (TNF- $\alpha$ ), interleukin-6 (IL-6) and interferon-gamma (IFN- $\gamma$ ) and increase the production of human chorionic gonadotropin (hCG) in the trophoblast *in vitro* [22].

The normal level of Vitamin D was predominant in women with endometriosis, which is not consistent with other studies [23,24] that observed an association of low levels of 25(OH)D with a significantly increased risk of endometriosis. This data can be justified by the small number of cases of endometriosis in our study and the genetic predisposition. Two elements argue in favor of a potential relationship of vitamin D and endometriosis based on the expression of VDR in the endometrium [25].

We found a significant association between vitamin D and miscarriage, which was confirmed by other studies showing that the human placenta is a key tissue for the accumulation of 25(OH)D and 1,25-dihydroxy vitamin D active (1,25(OH) $_2$ D) [26], with the potential to exert significant effects on trophoblast invasion, remodeling of the placental spiral artery and function of immune cells [27]. These processes are altered in human miscarriages, with aberrant endometrial receptivity and dysregulated placentation noted shortly after initial conception [28,29]. It is, therefore, possible that a low serum level of 25(OH)D contributes to the physiology of miscarriage through a concomitant decrease in placental 1,25(OH) $_2$ D level and the resulting placental dysregulation [30].

The expression of vitamin D receptors in the endometrium and the role of vitamin D in the transcription of the HOX10A gene (which has been shown to be important in implantation) suggest that the immunomodulatory effects of vitamin D could have a direct impact on implantation and, hence, the probability of success of reproductive treatment [31], which explains the relationship between vitamin D deficiency and abortion.

According to the conclusions of a study by Li *et al.* [32], women with normal vitamin D rates are less likely to have fibroids than others, which is in agreement with our results.

Regarding ovarian steroidogenesis, human ovarian cells trigger progesterone and estradiol secretion in the presence of calcitriol [30]. This may confirm the significant correlation found between estrogen, progesterone – and vitamin D ( $P < 0.0001$ ). Other experimental studies [33] reported an influence of the metabolites of vitamin D on the production of reproductive hormones. Indeed, granulosa cells contain vitamin D receptors (VDR), and *in vitro* stimulation of human ovarian cells by 1,25(OH) $_2$ D (1,25-dihydroxy vitamin D) affects ovarian steroidogenesis [34].

The experimental effect of vitamin D on estrogens is, however, clearer. Studies on human granulosa cells [35] porcine [36] and caprine [37] have revealed a stimulating

effect of 1,25(OH)<sub>2</sub> D<sub>3</sub> on estradiol (E<sub>2</sub>) and aromatase enzyme.

Kolcsár *et al.*, [31] found that serum 25-hydroxy vitamin D levels of approximately 20 ng/mL may be necessary to trigger ovulation or to support progesterone secretion. This explains the significant relationship between progesterone and vitamin D in our study.

The chi-squared and ANOVA test showed a significant relationship between FSH and vitamin D, which is consistent with literature findings [38] that claimed that vitamin D can also play a role in modulating FSH sensitivity and selecting dominant follicles in granulosa cells, through down-regulation of the FSH receptor. On the other hand, no significant relationship was found between LH and vitamin D.

Supplementation should be individualized based on measured concentration (give more vitamin D to those with lower concentrations) [39]. After an initial dosage of 25OHD, a regimen of 50,000 IU per week for eight weeks in those with a 25OHD concentration <20 ng/mL, or 50,000 IU weekly for four weeks in those with a 25OHD concentration between 20 and 30 ng/mL is recommended. This rapid “recharge” period should then be followed by a maintenance treatment of 50,000 IU/month. The effectiveness of this should be evaluated after 3 to 6 months by measuring the 25OHD and possibly readjusting the dosage. If the 25OHD is still <30 ng/mL, dose interval could be reduced, i.e: 50,000 IU every 2 weeks, or an increased dosage (for example: 80,000 or 100,000 IU per month) applied [39]. Our patients did not respect this therapeutic regimen, which explains the absence of positive results after supplementation.

## CONCLUSION

If vitamin D is fundamental for good fertility and increased pregnancy, it is partly due to its contribution to the induction of sex hormones production by the body, the improvement of the menstrual cycle, and its beneficial effects on the characteristics of PCOS and other conditions associated with female infertility. Thus, good control of vitamin D levels is important for improving female fertility.

## LIMIT

Some patients refused to participate in the study or sign their consent, others did not have the full evaluation of biological analyses, particularly vitamin D, due to its expensive price.

## ACKNOWLEDGEMENTS

The authors give special thanks the participants for their invaluable support, guidance, and educational insight.

## CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

## ORCID iDs

Anfal Belkacem <https://orcid.org/0000-0001-5927-3853>  
 Siheme Ouali <https://orcid.org/0000-0002-1767-3397>  
 Noria Harir <https://orcid.org/0000-0002-5221-2705>  
 Ferial Sellam <https://orcid.org/0000-0003-4423-5699>

Khalida Zemri <https://orcid.org/0000-0002-5239-5046>  
 Chahanz Hadj Slimane Mirali

<https://orcid.org/0009-0009-5182-6324>

Malika Bendaheman <https://orcid.org/0009-0000-8127-4377>

Feryel Senoussaoui <https://orcid.org/0009-0007-8645-7114>

Seif Eddine Benariba <https://orcid.org/0009-0000-5341-4491>

## REFERENCES

- Bhattarai HK, Shrestha S, Rokka K, Shakya R. Vitamin D, Calcium, parathyroid hormone, and sex steroids in bone health and effects of aging. *J Osteoporos.* 2020;2020:1-10.
- Da Silveira EA, Moura LDANE, Castro MCR, Kac G, Hadler MCCM, Noll PRES, et al. Prevalence of vitamin D and calcium deficiency and insufficiency in women of childbearing age and associated risk factors: A systematic review and meta-analysis. *Nutrients.* 2022; 14(20):4351.
- Al Faris NA, Al Kehayez NM, Al Mushawah FI, Al Naeem AN, Al Amri ND, Al Mudawah ES. Vitamin D deficiency and associated risk factors in women from Riyadh, Saudi Arabia. *Sci Rep.* 2019;9(1): 20371.
- Jueraitetibaike K, Ding Z, Wang DD, Peng LP, Jing J, Chen L, et al. The effect of vitamin D on sperm motility and the underlying mechanism. *Asian J Androl.* 2019;21(4):400.
- Hrabia A, Kamińska K, Socha M, Grzesiak M. Vitamin D<sub>3</sub> receptors and metabolic enzymes in hen reproductive tissues. *IJMS.* 2023; 24(23):17074.
- [<https://www.who.int/news-room/fact-sheets/detail/infertility>]
- Collée J, Mawet M, Tebache L, Nisolle M, Brichant G. Polycystic ovarian syndrome and infertility: overview and insights of the putative treatments. *Gynecol Endocrinol.* 2021;37(10):869-74.
- Zauner G, Girardi G. Potential causes of male and female infertility in Qatar. *J Reprod Immunol.* 2020;141:103173.
- Gruber TM, Mechsner S. Pathogenesis of endometriosis: The origin of pain and subfertility. *Cells.* 2021;10(6):1381.
- Nasreen K, Ishrat S, Banu J, Fatima P, Ansary SA, Jahan I, et al. Comparison of vitamin D (25OHD) status between fertile and infertile men. *Int J Reprod Contracept Obstet Gynecol.* 2021; 10(4):1303.
- Grzesiak M. Vitamin D<sub>3</sub> Action within the ovary – an updated review. *Physiol Res.* 2020; 69(3): 371-8.
- Hadri Z, Benada M, Djellouli M, Boudalia S, Rahali A, Araf A. Prevalence of obesity and effect of sport activity on university students in Algeria. *Sci Afr.* 2022;17:e01319.
- Karampela I, Sakelliou A, Vallianou N, Christodoulatos GS, Magkos F, Dalamaga M. Vitamin D and obesity: Current evidence and controversies. *Curr Obes Rep.* 2021;10(2):162-80.
- Vranić L, Mikolašević I, Milić S. Vitamin D deficiency: consequence or cause of obesity? *Medicina.* 2019;55(9):541.
- Holick MF, Slominski AT. Photobiology of vitamin D. In: *Feldman and Pike's Vitamin D*. Elsevier; 2024:27-45.
- Fung JL, Hartman TJ, Schleicher RL, Goldman MB. Association of vitamin D intake and serum levels with fertility: results from the lifestyle and fertility study. *Fertil Steril.* 2017;108(2):302-11.
- Azhar A, Abid F, Rehman R. Polycystic ovary syndrome, subfertility and vitamin d deficiency. *J Coll Physicians Surg Pak.* 2020;30(05): 545-6.
- Di Bari F, Catalano A, Bellone F, Martino G, Benvenga S. Vitamin D, bone metabolism, and fracture risk in polycystic ovary syndrome. *Metabolites.* 2021;11(2):116.
- MotlaghAsghari K, Nejadghaderi SA, Alizadeh M, Sanaie S, Sullman MJM, Kolahi AA, et al. Burden of polycystic ovary syndrome in the Middle East and North Africa region, 1990-2019. *Sci Rep.* 2022;12(1):7039.
- Schröder-Heurich B, Springer CJP, Von Versen-Höyneck F. Vitamin D effects on the immune system from periconception through pregnancy. *Nutrients.* 2020;12(5):1432.
- Tavakoli M, Jeddi-Tehrani M, Salek-Moghaddam A, Rajaei S, Mohammadzadeh A, Sheikhhasani S, et al. Effects of 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> on cytokine production by endometrial cells of women with recurrent spontaneous abortion. *Fertil Steril.* 2011;96(3):751-7.

22. Várbiro S, Takács I, Túó L, Nas K, Sziva RE, Hetthéssy JR, et al. Effects of Vitamin D on fertility, pregnancy and polycystic ovary syndrome – a review. *Nutrients*. 2022;14(8):1649.
23. Grzesiak M. Vitamin D3 Action within the ovary – an updated review. *Physiol Res*. 2020;69(3):371-8.
24. Qiu Y, Yuan S, Wang H. Vitamin D status in endometriosis: a systematic review and meta-analysis. *Arch Gynecol Obstet*. 2020;302(1):141-52.
25. De Pascali F, Casarini L, Kuhn C, Simoni M, Mahner S, Jeschke U, et al. Nuclear expression of VDR and AHR is mutually exclusive in glandular cells in endometriosis. *Histochem Cell Biol*. 2021;156(4):391-9.
26. Tamblin JA, Susarla R, Jenkinson C, Jeffery LE, Ohizua O, Chun RF, et al. Dysregulation of maternal and placental vitamin D metabolism in preeclampsia. *Placenta*. 2017;50:70-7.
27. Zhang JY, Wu P, Chen D, Ning F, Lu Q, Qiu X, et al. Vitamin D promotes trophoblast cell induced separation of vascular smooth muscle cells in vascular remodeling via induction of G-CSF. *Front Cell Dev Biol*. 2020;8:601043.
28. Dimitriadis E, Menkhorst E, Saito S, Kuttah WH, Brosens JJ. Recurrent pregnancy loss. *Nat Rev Dis Primers*. 2020;6(1):98.
29. Lucas ES, Vrljicak P, Muter J, Diniz-da-Costa MM, Brighton PJ, Kong CS, et al. Recurrent pregnancy loss is associated with a pro-senescent decidual response during the peri-implantation window. *Commun Biol*. 2020;3(1):37.
30. Tamblin JA, Pilarski NSP, Markland AD, Marson EJ, Devall A, Hewison M, et al. Vitamin D and miscarriage: a systematic review and meta-analysis. *Fertil Steril*. 2022;118(1):111-22.
31. Kolcsár M, Berecki B, Gáll Z. Relationship between serum 25-Hydroxyvitamin D levels and hormonal status in infertile women: A retrospective study. *Diagnostics*. 2023;13(19):3024.
32. Li S, Chen B, Sheng B, Wang J, Zhu X. The associations between serum vitamin D, calcium and uterine fibroids in Chinese women: a case-controlled study. *J Int Med Res*. 2020;48(5):030006052092349.
33. Harmon QE, Kissell K, Jukic AMZ, Kim K, Sjaarda L, Perkins NJ, et al. Vitamin D and reproductive hormones across the menstrual cycle. *Hum Reprod*. 2020;35(2):413-23.
34. Cheng M, Song Z, Guo Y, Luo X, Li X, Wu X, et al. 1 $\alpha$ ,25-Dihydroxyvitamin D3 Improves Follicular Development and Steroid Hormone Biosynthesis by Regulating Vitamin D Receptor in the Layers Model. *CIMB*. 2023;45(5):4017-34.
35. Parikh G, Varadinova M, Suwandhi P, Araki T, Rosenwaks Z, Poretsky L, et al. Vitamin D regulates steroidogenesis and insulin-like growth factor binding Protein-1 (IGFBP-1) production in human ovarian cells. *Horm Metab Res*. 2010;42(10):754-7.
36. Hong SH, Lee JE, An SM, Shin YY, Hwang DY, Yang SY, et al. Effect of Vitamin D3 on biosynthesis of estrogen in porcine granulosa cells via modulation of steroidogenic enzymes. *Toxicol Res*. 2017;33(1):49-54.
37. Yao X, Zhang G, Guo Y, El-Samahy M, Wang S, Wan Y, et al. Vitamin D receptor expression and potential role of vitamin D on cell proliferation and steroidogenesis in goat ovarian granulosa cells. *Theriogenology*. 2017;102:162-73.
38. Merhi Z, Doswell A, Krebs K, Cipolla M. Vitamin D alters genes involved in follicular development and steroidogenesis in human cumulus granulosa cells. *J Clin Endocrinol Metab*. 2014;99(6):E1137-45.
39. Souberbielle JC, Cormier C, Cavalier E, Breuil V, Debiais F, Fardellone P, et al. La supplémentation en vitamine D en France chez les patients ostéoporotiques ou à risque d'ostéoporose: données récentes et nouvelles pratiques. *Rev Rhum*. 2019;86(5):448-52.